LANTIDRA (donislecel-jujn)

About CellTrans

CellTrans is a private, clinical-stage biotech focused on functional cures through cell transplantation, most notably with its FDA-approved therapy LANTIDRA for Type 1 diabetes. The company operates a dual business model, combining its own therapeutic development with a fee-for-service arm offering pre-clinical, clinical, and in-vitro testing services for external clients. Led by a founder with deep clinical transplant expertise and supported by a seasoned operational team, CellTrans leverages its cGMP manufacturing and quality systems to advance its pipeline and support partners in the cell and gene therapy space.

Therapeutic Areas